Lawrence A Leiter Selected Research

oxidized low density lipoprotein

5/2024	Weight management using meal replacements and cardiometabolic risk reduction in individuals with pre-diabetes and features of metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials.
1/2024	Real-World Risk of Recurrent Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with LDL-C Above Guideline-Recommended Threshold: A Retrospective Observational Study.
12/2023	Rationale and Design of the Effect of EVolocumab in PatiEntS at High CArdiovascuLar RIsk WithoUt Prior Myocardial Infarction or Stroke (VESALIUS-CV) Trial.
12/2023	Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials.
9/2023	Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria.
6/2023	Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11.
1/2023	Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
12/2022	Effect of inclisiran on lipids in primary prevention: the ORION-11 trial.
5/2022	Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials.
1/2022	Validating the NIH LDL-C equation in a specialized lipid cohort: Does it add up?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lawrence A Leiter Research Topics

Disease

176	Type 2 Diabetes Mellitus (MODY) 04/2024 - 09/2002
96	Cardiovascular Diseases (Cardiovascular Disease) 03/2024 - 01/2003
61	Myocardial Infarction 04/2024 - 01/2005
54	Heart Failure 12/2023 - 06/2005
41	Stroke (Strokes) 04/2024 - 01/2005
29	Body Weight (Weight, Body) 05/2024 - 09/2002
29	Coronary Artery Disease (Coronary Atherosclerosis) 04/2024 - 08/2002
25	Diabetes Mellitus 04/2024 - 01/2002
22	Hypertension (High Blood Pressure) 01/2023 - 01/2005
21	Dyslipidemias (Dyslipidemia) 12/2023 - 06/2005
20	Coronary Disease (Coronary Heart Disease) 01/2024 - 07/2006
20	Hypoglycemia (Reactive Hypoglycemia) 01/2023 - 04/2010
17	Chronic Renal Insufficiency 04/2024 - 06/2005
17	Hypercholesterolemia 12/2023 - 12/2002
16	Weight Loss (Weight Reduction) 05/2024 - 09/2010
15	Atherosclerosis 04/2024 - 01/2005
14	Ischemic Stroke 01/2024 - 11/2012
13	Acute Coronary Syndrome 09/2020 - 07/2003
12	Albuminuria 01/2021 - 06/2005
10	Cerebrovascular Disorders (Cerebrovascular Occlusion) 06/2023 - 05/2007
10	Unstable Angina 01/2023 - 01/2005
10	Infections 01/2023 - 01/2005
9	Metabolic Syndrome (Dysmetabolic Syndrome X) 05/2024 - 01/2007
9	Glucose Intolerance 12/2013 - 01/2005
8	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 11/2023 - 11/2019
8	Hyperglycemia 01/2023 - 01/2005
8	Overweight 01/2023 - 02/2012
8	Kidney Diseases (Kidney Disease) 01/2023 - 07/2011
7	Obesity 05/2024 - 11/2010
7	Insulin Resistance 07/2020 - 01/2005
7	Isolated Systolic Hypertension 01/2017 - 06/2005
5	Hemorrhage 04/2024 - 09/2019
5	Hyperlipidemias (Hyperlipidemia) 06/2023 - 09/2007
5	Prediabetic State (Prediabetes) 01/2022 - 12/2017
5	Atrial Fibrillation 01/2022 - 01/2012

Drug/Important Bio-Agent (IBA)

63	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 03/2024 - 07/2003
48	Glucose (Dextrose)FDA LinkGeneric 01/2023 - 12/2004
47	LipidsIBA 12/2023 - 01/2002
39	LDL CholesterolIBA 01/2024 - 05/2005
36	oxidized low density lipoproteinIBA 05/2024 - 01/2005
31	CholesterolIBA 11/2022 - 12/2002
30	dapagliflozinIBA 01/2023 - 07/2014
26	Insulin (Novolin)FDA Link 02/2023 - 01/2005
21	Sodium-Glucose Transport ProteinsIBA 01/2023 - 09/2013
20	omega-Chloroacetophenone (Mace)IBA 04/2024 - 01/2018
17	SodiumIBA 01/2023 - 05/2014
16	FructoseIBA 01/2023 - 02/2012
15	Glucagon-Like Peptide-1 Receptor AgonistsIBA 02/2024 - 01/2016
15	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2023 - 11/2016
15	Hypoglycemic Agents (Hypoglycemics)IBA 01/2021 - 06/2006
14	Glucagon-Like Peptide-1 ReceptorIBA 02/2024 - 08/2014
14	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2023 - 09/2013
14	Atorvastatin (Lipitor)FDA Link 06/2013 - 01/2003
12	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 04/2024 - 06/2005
12	HDL CholesterolIBA 12/2023 - 01/2012
12	semaglutideIBA 01/2023 - 11/2016
11	Biomarkers (Surrogate Marker)IBA 07/2023 - 05/2007
10	ALN-PCSIBA 05/2024 - 01/2017
10	Triglycerides (Triacylglycerol)IBA 03/2024 - 12/2010
10	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 02/2023 - 01/2008
10	SugarsIBA 01/2023 - 01/2014
10	dulaglutideIBA 10/2022 - 01/2018
10	CreatinineIBA 01/2022 - 01/2012
10	Ezetimibe (Zetia)FDA Link 09/2020 - 01/2003
10	Blood Glucose (Blood Sugar)IBA 10/2018 - 09/2002
10	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2018 - 06/2005
9	TicagrelorIBA 04/2024 - 05/2019
9	empagliflozinIBA 01/2023 - 10/2019
9	Liraglutide FDA Link 01/2022 - 01/2016
9	Metformin (Glucophage)FDA LinkGeneric 01/2021 - 06/2006
8	rGLP-1 proteinIBA 02/2024 - 08/2014
8	Proteins (Proteins, Gene)FDA Link 11/2022 - 01/2007
8	AlbuminsIBA 01/2022 - 07/2011
8	alirocumabIBA 01/2020 - 01/2017
8	Angiotensin Receptor AntagonistsIBA 01/2018 - 06/2005
7	SymportersIBA 01/2023 - 04/2015
7	8- hydroxy- 2,2,14,14- tetramethylpentadecanedioic acidIBA 05/2022 - 10/2018
7	Insulin Glargine (Lantus)FDA Link 01/2022 - 10/2013
7	Rosuvastatin Calcium (Crestor)FDA Link 01/2021 - 10/2007
7	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2016 - 06/2005
7	Valsartan (Vals)FDA Link 12/2013 - 01/2005
7	Nateglinide (Starlix)FDA LinkGeneric 12/2013 - 01/2005
7	1,4-dihydropyridine (dihydropyridine)IBA 07/2011 - 06/2005
6	(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA 04/2024 - 01/2021
6	Proprotein Convertase 9IBA 12/2023 - 01/2017
6	CarbohydratesIBA 11/2022 - 01/2008
6	saxagliptin FDA Link 11/2021 - 10/2013
6	IncretinsIBA 11/2020 - 02/2010
6	DiureticsIBA 01/2020 - 05/2007
6	CanagliflozinIBA 01/2018 - 09/2013
6	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 07/2011 - 06/2005
6	ThiazidesIBA 05/2010 - 06/2005
5	ApolipoproteinsIBA 12/2023 - 09/2002
5	HDL LipoproteinsIBA 11/2022 - 11/2012

Therapy/Procedure

77	Therapeutics 04/2024 - 01/2003
27	Glycemic Control 11/2022 - 09/2002
8	Secondary Prevention 06/2023 - 12/2007
7	Subcutaneous Injections 01/2021 - 01/2017
6	Percutaneous Coronary Intervention 01/2023 - 12/2013
5	Surgical Amputation (Amputations) 04/2024 - 01/2020